MYLAN-VERAPAMIL SR 240 MG
VERAPAMIL HYDROCHLORIDE : 240 MG · DIN 02210363 · MYLAN PHARMACEUTICALS ULC
Health Canada status: CANCELLED POST MARKET
What is MYLAN-VERAPAMIL SR?
MYLAN-VERAPAMIL SR 240 MG contains VERAPAMIL HYDROCHLORIDE : 240 MG. It is listed in the Health Canada Drug Product Database under DIN 02210363, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 13-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-VERAPAMIL SR used for?
Treatment of mild to moderate essential hypertension. (Max 200 chars)
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is MYLAN-VERAPAMIL SR called?
The same molecule, VERAPAMIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Isoptin SR | Latin | Australia, South Africa |
| Cordilox SR | Latin | Australia |
| FIBROCARD LP | Latin | Morocco |
| Isoptin | Latin | Australia |
| Isoptin ICHS retard | Latin | Slovakia |
| Sandoz Verapamil | Latin | South Africa |
| Vasomil Injection | Latin | South Africa |
| VeraHexal | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02210363 |
|---|---|
| Brand name | MYLAN-VERAPAMIL SR |
| Generic / active ingredient | VERAPAMIL HYDROCHLORIDE : 240 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 240 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08DA01 VERAPAMIL |
| AHFS class | 24:28.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-Jun-2022 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02210363 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2210363 |
| Brand name | MYLAN-VERAPAMIL SR |
| Active ingredient / INN | VERAPAMIL HYDROCHLORIDE : 240 MG |
| ATC code | C08DA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C08 |
| AHFS class | 24:28.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
How is it administered?
For essential hypertension. Dosage must be individualized. Normally used in patients where diuretics or beta-blockers are associated with unacceptable adverse effects or are contraindicated.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to 'STORAGE AND STABILITY' section).
How is it supplied?
Not explicitly stated in provided text (refer to full monograph section 'DOSAGE FORMS, COMPOSITION AND PACKAGING').
Which pack is which?
| Strength on the label | 240 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | Not explicitly stated in provided text (refer to full monograph section 'DOSAGE FORMS, COMPOSITION AND PACKAGING'). |
| Storage | Not explicitly stated in provided text (refer to 'STORAGE AND STABILITY' section). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; complicated MI; severe LV dysfunction; cardiogenic shock; severe hypotension; 2nd/3rd degree A-V block; sick sinus syndrome; marked bradycardia; atrial flutter/fibrillation with WPW.
Warnings and precautions
Avoid in poorly compensated heart failure. Can cause hypotension, bradycardia, and A-V block. Monitor liver function. Caution in neuromuscular transmission disorders (e.g., myasthenia gravis).
What can be used instead?
Other Canadian products sharing ATC code C08DA01 VERAPAMIL. 5 of 53 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-VERAP TAB 80MG | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 00782483 |
| APO-VERAP TABLET 120MG | 120 MG | TABLET | APOTEX INC | MARKETED | DIN 00782491 |
| ISOPTIN SR | 120 MG | TABLET (EXTENDED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 01907123 |
| MYLAN-VERAPAMIL SR | 120 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02210347 |
| VERAPAMIL HYDROCHLORIDE INJECTION USP | 2.5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166739 |
| ALTI-VERAPAMIL - 120MG | 120 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00867373 |
| ALTI-VERAPAMIL - 80MG | 80 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00867365 |
| APO-VERAP SR | 120 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246893 |
| APO-VERAP SR | 180 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246894 |
| APO-VERAP SR | 240 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246895 |
Who else supplies VERAPAMIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VERAPAMIL appears in 107 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does VERAPAMIL cost around the world?
VERAPAMIL is listed on 10 national price registers Nexara tracks, across 81 pack listings published on 9 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 15 | 19 | 01 Sep 2026 |
| United States | acquisition | 3 | 13 | 03 Sep 2026 |
| Australia | ex-manufacturer | 6 | 12 | 08 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 12 | 12 | 02 Sep 2026 |
| Romania | max producer price | 5 | 6 | 03 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Slovakia | categorised final price | 5 | 5 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Morocco | PPV (public price) | 1 | 2 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.